AR113839A1 - Antagonistas del receptor b2 de bradiquinina - Google Patents
Antagonistas del receptor b2 de bradiquininaInfo
- Publication number
- AR113839A1 AR113839A1 ARP180103444A ARP180103444A AR113839A1 AR 113839 A1 AR113839 A1 AR 113839A1 AR P180103444 A ARP180103444 A AR P180103444A AR P180103444 A ARP180103444 A AR P180103444A AR 113839 A1 AR113839 A1 AR 113839A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- independently
- halogen atom
- substituted
- hydrogen atom
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 102000010183 Bradykinin receptor Human genes 0.000 abstract 2
- 108050001736 Bradykinin receptor Proteins 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 125000004431 deuterium atom Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a un compuesto de acuerdo con la formula general (1), que actúa como un antagonista del receptor de bradiquinina (BK) B2; a una composición farmacéutica que contiene uno o más compuestos de la presente; a una preparación de combinación que contiene al menos un compuesto de la presente y al menos otro principio farmacéuticamente activo adicional; y a los usos de dicho(s) compuesto(s), incluido el uso como medicamento. Reivindicación 1: Un compuesto de fórmula general (1) o una de sus sales, en la que A representa un grupo del grupo de fórmulas (2); A¹ es N o CH; A² es N o C-RA²; A³ es N o C-RA³; A⁴ es NH, O ó S; A⁵ es N-RA⁵; RA¹ representa un átomo de hidrógeno o un grupo metilo; cada uno de RA² y RA³, independientemente entre sí, representa un átomo de hidrógeno, un átomo de halógeno, OH, CN, NH₂; alquilo C₁₋₃, que puede estar sustituido con uno o más, grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; alcoxi C₁₋₃, que puede estar sustituido con uno o más grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; alcoxialquilo C₂₋₅, que puede estar sustituido con uno o más, grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; C(O)NRB¹RB²; o NRB¹RB²; RB¹, RB² y RA⁵, cada uno independientemente entre sí, representa un átomo de hidrógeno o un grupo alquilo C₁₋₃, que puede estar sustituido con uno o más, grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; R¹ representa un grupo alquilo C₁₋₃ o alcoxialquilo C₂₋₅, dicho grupo alquilo o alcoxialquilo puede estar sustituido con uno o más grupo(s), idénticos o diferentes, seleccionados entre un átomo de deuterio, un átomo de halógeno, OH, =O y NH₂; R² representa un átomo de hidrógeno o un átomo de deuterio; R³ representa un átomo de hidrógeno, un grupo alquilo C₁₋₃ o haloalquilo C₁₋₃; E representa CRE¹RE²RE³ o Hce; Hce representa un heterociclo mono o bicíclico, parcialmente insaturado o aromático, que tiene de 3 a 10 átomos de C y de 1 a 4 heteroátomo(s) cada uno independientemente entre sí, seleccionados de N, O ó S, dicho heterociclo está no sustituido o puede estar monosustituido, disustituido o trisustituido, en cada ocasión independientemente, con un átomo de halógeno, OH, G, NRC¹RC² y/u =O; cada uno de RC¹ y RC², independientemente entre sí, representan un átomo de hidrógeno o un grupo alquilo C₁₋₃; G representa un grupo alquilo C₁₋₆, en el que de 1 a 7 átomos de H pueden, en cada ocasión independientemente, estar sustituidos con un átomo de halógeno, ORG¹, CN, NRG²RG³ o cicloalquilo C₃₋₆, y/o en el que un grupo CH₂, o dos grupos CH₂ no adyacentes, pueden estar sustituidos con O, C(O), OC(O), C(O)O, C(O)NH, NH, S, SO, SO₂ y/o por un grupo CH=CH; RG¹, RG² y RG³, cada uno independientemente entre sí, representan un átomo de hidrógeno, un grupo alquilo C₁₋₄, haloalquilo C₁₋₄, hidroxialquilo C₁₋₄, heteroalquilo C₁₋₄ o cicloalquilo C₃₋₆; RE¹ y RE², cada uno independientemente entre sí, representan un átomo de hidrógeno, un átomo de halógeno, o G; o RE¹ y RE² tomados juntos forman =O ó Cyc; RE³ representa un átomo de hidrógeno, un átomo de halógeno, G, OG u OH; y Cyc representa un grupo cicloalquilo mono o bicíclico, saturado o parcialmente insaturado de 3 a 10 miembros o un grupo heterocicloalquilo de 4 a 10 miembros que tiene de 1 a 3 heteroátomo(s) cada uno independientemente entre sí, seleccionados de N, O ó S, dicho grupo cicloalquilo o heterocicloalquilo está no sustituido o puede estar monosustituido, disustituido, trisustituido, o tetrasustituido, en cada ocasión independientemente con un átomo de halógeno, OH, G, NRC¹RC² y/u =O.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203675 | 2017-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113839A1 true AR113839A1 (es) | 2020-06-17 |
Family
ID=60473364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103444A AR113839A1 (es) | 2017-11-24 | 2018-11-23 | Antagonistas del receptor b2 de bradiquinina |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10836748B2 (es) |
| EP (2) | EP3713928B1 (es) |
| JP (2) | JP7164619B2 (es) |
| KR (1) | KR102413321B1 (es) |
| CN (1) | CN111433196B (es) |
| AR (1) | AR113839A1 (es) |
| AU (1) | AU2018371186B2 (es) |
| BR (1) | BR112020010298A2 (es) |
| CA (1) | CA3082948A1 (es) |
| CY (1) | CY1125348T1 (es) |
| DK (1) | DK3713928T3 (es) |
| EA (1) | EA202091256A1 (es) |
| ES (1) | ES2908409T3 (es) |
| HR (1) | HRP20220429T1 (es) |
| HU (1) | HUE058217T2 (es) |
| IL (1) | IL274883B2 (es) |
| LT (1) | LT3713928T (es) |
| MA (1) | MA50804B1 (es) |
| MX (1) | MX2020005287A (es) |
| PH (1) | PH12020550683A1 (es) |
| PL (1) | PL3713928T3 (es) |
| PT (1) | PT3713928T (es) |
| RS (1) | RS63087B1 (es) |
| SG (1) | SG11202004653TA (es) |
| SI (1) | SI3713928T1 (es) |
| TW (1) | TWI768156B (es) |
| UY (1) | UY37981A (es) |
| WO (1) | WO2019101906A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR113839A1 (es) | 2017-11-24 | 2020-06-17 | Pharvaris B V | Antagonistas del receptor b2 de bradiquinina |
| UY38706A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| AR118983A1 (es) * | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| IL302887A (en) | 2020-11-12 | 2023-07-01 | Pharvaris Gmbh | Prevention and treatment of angioedema |
| EP4380929A1 (en) | 2021-08-05 | 2024-06-12 | Pharvaris GmbH | Solid form of a bradykinin b2-receptor antagonist |
| RS65427B1 (sr) | 2021-08-05 | 2024-05-31 | Pharvaris Gmbh | Kompozicija na bazi lipida za oralnu primenu antagonista receptora bradikinina b2 |
| WO2023180575A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
| TW202345810A (zh) | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物 |
| WO2023180577A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Therapeutic uses of bradykinin b2-receptor antagonists |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680870B2 (en) | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| ES2218554T3 (es) | 1994-10-27 | 2004-11-16 | Fujisawa Pharmaceutical Co., Ltd. | Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina. |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE19612067A1 (de) | 1996-03-27 | 1997-10-02 | Hoechst Ag | Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| CA2319730A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Bradykinin antagonists |
| BR9914785A (pt) | 1998-10-21 | 2001-07-03 | Fujisawa Pharmaceutical Co | Formavìtrea de 8-[3-[n-[(e)-3-(6-acetamidopiridin-3-il) acriloilglicil]-n-metilamino]-2,6-diclorobenziloxi)-2- metilquinolina, processo para sua preparação, composição farmacêutica compreendendo a mesma, agente de prevenção, seu métodos e uso |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| WO2001056995A1 (en) | 2000-01-18 | 2001-08-09 | Nuerogen Corporation | Substituted imidazoles as selective modulators of bradykinin b2 receptors |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| EP1495017A2 (en) | 2002-04-10 | 2005-01-12 | Ortho-McNeil Pharmaceutical, Inc. | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| EP1741444A1 (en) | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| TWI407960B (zh) * | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) * | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| CA2904052A1 (en) | 2013-03-14 | 2014-10-02 | Shire Human Genetic Therapies, Inc. | Methods of treating b2-bradykinin receptor mediated angioedema |
| AR113839A1 (es) | 2017-11-24 | 2020-06-17 | Pharvaris B V | Antagonistas del receptor b2 de bradiquinina |
-
2018
- 2018-11-23 AR ARP180103444A patent/AR113839A1/es unknown
- 2018-11-23 AU AU2018371186A patent/AU2018371186B2/en active Active
- 2018-11-23 HU HUE18818992A patent/HUE058217T2/hu unknown
- 2018-11-23 WO PCT/EP2018/082338 patent/WO2019101906A1/en unknown
- 2018-11-23 ES ES18818992T patent/ES2908409T3/es active Active
- 2018-11-23 UY UY0001037981A patent/UY37981A/es unknown
- 2018-11-23 HR HRP20220429TT patent/HRP20220429T1/hr unknown
- 2018-11-23 CA CA3082948A patent/CA3082948A1/en active Pending
- 2018-11-23 KR KR1020207017972A patent/KR102413321B1/ko active IP Right Grant
- 2018-11-23 CN CN201880076162.XA patent/CN111433196B/zh active Active
- 2018-11-23 EP EP18818992.2A patent/EP3713928B1/en active Active
- 2018-11-23 BR BR112020010298-9A patent/BR112020010298A2/pt unknown
- 2018-11-23 SI SI201830628T patent/SI3713928T1/sl unknown
- 2018-11-23 LT LTEPPCT/EP2018/082338T patent/LT3713928T/lt unknown
- 2018-11-23 EA EA202091256A patent/EA202091256A1/ru unknown
- 2018-11-23 MX MX2020005287A patent/MX2020005287A/es unknown
- 2018-11-23 DK DK18818992.2T patent/DK3713928T3/da active
- 2018-11-23 JP JP2020545875A patent/JP7164619B2/ja active Active
- 2018-11-23 SG SG11202004653TA patent/SG11202004653TA/en unknown
- 2018-11-23 EP EP21213719.4A patent/EP3998259A1/en active Pending
- 2018-11-23 IL IL274883A patent/IL274883B2/en unknown
- 2018-11-23 TW TW107141872A patent/TWI768156B/zh active
- 2018-11-23 RS RS20220335A patent/RS63087B1/sr unknown
- 2018-11-23 PT PT188189922T patent/PT3713928T/pt unknown
- 2018-11-23 PL PL18818992T patent/PL3713928T3/pl unknown
- 2018-11-23 MA MA50804A patent/MA50804B1/fr unknown
-
2020
- 2020-04-28 US US16/861,131 patent/US10836748B2/en active Active
- 2020-05-21 PH PH12020550683A patent/PH12020550683A1/en unknown
- 2020-09-25 US US17/033,347 patent/US11261173B2/en active Active
-
2022
- 2022-01-18 US US17/578,161 patent/US11820756B2/en active Active
- 2022-04-11 CY CY20221100272T patent/CY1125348T1/el unknown
- 2022-10-20 JP JP2022168473A patent/JP2023002701A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113839A1 (es) | Antagonistas del receptor b2 de bradiquinina | |
| UY37845A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| AR106605A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
| AR118983A1 (es) | Antagonistas cíclicos del receptor b2 de bradiquinina | |
| AR114971A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| PE20191260A1 (es) | Compuestos inhibidores del vih | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR094550A1 (es) | Inhibidores de btk | |
| AR111983A1 (es) | ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| AR111841A1 (es) | ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES DE C5a | |
| AR090596A1 (es) | Formulaciones farmaceuticas que comprenden antagonistas de ccr3 | |
| AR094100A1 (es) | DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS b2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
| TR201904639T4 (tr) | Muskarinik M1 reseptörü pozitif allosterik modülatörler. | |
| AR122703A1 (es) | Inhibidores de rip1k | |
| AR098436A1 (es) | Compuestos tricíclicos de piperidina | |
| CL2018000839A1 (es) | Derivados de 2-aminoquinazolina como inhibidores de la quinasa p70s6 | |
| UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
| AR104749A1 (es) | Imidazo[1,2-b][1,2,4]triazina sustituida, composición farmacéutica y combinación que lo comprenden, y su uso para la fabricación de un medicamento | |
| AR111826A1 (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| AR103264A1 (es) | Derivados de 3,5-aminopirazol como inhibidores de quinasa rc |